On March 12, 2026, Artelo Biosciences, Inc. entered into two Securities Purchase Agreements, issuing bridge notes totaling $350,300 for $310,000 and plans to use the funds for general working capital. This includes a 12% interest rate and the potential for conversion to equity under certain conditions.